ACIU (AC Immune) E10: $-0.61 (As of Mar. 2026)


ACIU AC Immune SA ACIU
26 GF Score
Price $2.56
GF Value $0.75
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is AC Immune E10?

AC Immune ACIU +4.70% 26 E10 is $-0.61 as of Mar. 2026. GuruFocus rates ACIU with a GF Score™ of 26/100 and a GF Value™ of $0.75 (Significantly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

AC Immune's adjusted earnings per share data for the three months ended in Mar. 2026 was $-0.191. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-0.61 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-06-27), AC Immune's current stock price is $2.56. AC Immune's E10 for the quarter that ended in Mar. 2026 was $-0.61. AC Immune's Shiller PE Ratio of today is .


AC Immune  (NAS:ACIU) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


AC Immune E10 Related Terms


AC Immune E10 Historical Data

* Premium members only.

The historical data trend for AC Immune's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AC Immune E10 Chart

AC Immune Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.48 -0.60

AC Immune Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.50 -0.54 -0.60 -0.60 -0.61

ACIU vs TRDA, MGNX, SABS: E10 Comparison

For the Biotechnology subindustry, AC Immune's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AC Immune Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AC Immune's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where AC Immune's Shiller PE Ratio falls into.


ACIU
26GF Score
AC Immune SA ACIU
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AC Immune E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, AC Immune's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.191/107.1957*107.1957
=-0.191

Current CPI (Mar. 2026) = 107.1957.

AC Immune Quarterly Data

per share eps CPI Adj_EPS
201606 0.241 100.088 0.258
201609 -0.185 99.604 -0.199
201612 -0.088 99.380 -0.095
201703 -0.170 100.040 -0.182
201706 -0.227 100.285 -0.243
201709 -0.156 100.254 -0.167
201712 0.081 100.213 0.087
201803 -0.211 100.836 -0.224
201806 -0.192 101.435 -0.203
201809 -0.217 101.246 -0.230
201812 -0.212 100.906 -0.225
201903 0.910 101.571 0.960
201906 -0.243 102.044 -0.255
201909 0.252 101.396 0.266
201912 -0.285 101.063 -0.302
202003 -0.115 101.048 -0.122
202006 -0.231 100.743 -0.246
202009 -0.284 100.585 -0.303
202012 -0.304 100.241 -0.325
202103 -0.247 100.800 -0.263
202106 -0.286 101.352 -0.302
202109 -0.238 101.533 -0.251
202112 -0.282 101.776 -0.297
202203 -0.247 103.205 -0.257
202206 -0.237 104.783 -0.242
202209 -0.164 104.835 -0.168
202212 -0.247 104.666 -0.253
202303 -0.227 106.245 -0.229
202306 -0.222 106.576 -0.223
202309 -0.200 106.570 -0.201
202312 -0.058 106.461 -0.058
202403 -0.203 107.355 -0.203
202406 -0.257 107.991 -0.255
202409 0.059 107.468 0.059
202412 -0.179 107.128 -0.179
202503 -0.215 107.722 -0.214
202506 -0.258 108.075 -0.256
202509 -0.201 107.709 -0.200
202512 -0.176 107.196 -0.176
202603 -0.191 107.196 -0.191

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of $-0.61 mean?
AC Immune (ACIU) has a E10 of $-0.61 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on AC Immune and its competitors.
Is AC Immune's E10 too high?
AC Immune's current E10 is $-0.61. Overall, AC Immune has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AC Immune's E10 compare to TRDA and MGNX?
AC Immune's E10 of $-0.61 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on AC Immune and its competitors. AC Immune's current E10 is $-0.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AC Immune stock overvalued right now?
Based on GuruFocus' analysis, AC Immune (ACIU) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.75, compared to a current price of $2.56 — trading 241.3% above its estimated fair value. The current E10 is $-0.61. AC Immune's overall GF Score™ is 26/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For AC Immune (ACIU), the current E10 is $-0.61 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AC Immune (ACIU) Overvalued in 2026?

Based on GuruFocus' analysis, AC Immune stock appears to be overvalued. The current stock price of $2.56 is trading 241.3% above its estimated GF Value™ of $0.75. GuruFocus considers AC Immune to be Significantly Overvalued.

Key valuation signals for ACIU:

  • E10: $-0.61
  • GF Value™: $0.75 vs. price of $2.56 (241.3% above fair value)
  • GF Score™: 26/100 with 6 warning signs

No single metric tells the full story. See the ACIU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AC Immune Business Description

Other Exchanges IMR:Germany
Address EPFL Innovation Park, Building B, Lausanne, CHE, 1015
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
26GF Score

Get the complete analysis for ACIU

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.56
Price
$0.75
GF Value